3 results
The primary objective of this study is to demonstrate that eritoran tetrasodium treatment of patients with severe sepsis results in a reduction in 28-day all-cause mortality.The secondary objectives are to confirm eritoran*s safety profile, and to…
Primary end points:Safety (>1 toxic death per arm) and tolerability (relevant grade 4 toxicities) in not more than 33% of patients for the three treatment arms.Secondary end points:* Reduction of grade 2-4 key side effects in the experimental…
The aim of this study is to assess the effectivity of the Fluxion, in combination with Bluem (Bluem, Bluem Europe, Zwolle, The Netherlands) and in combination with demineralised water. This aims to find a minimally invasive treatment for peri-…